Impact of Dapagliflozin on Cardiac Function and Serum NT-proBNP and cTnⅠ Levels of Patients with Heart Failure with Reduced Ejection Fraction
Objective To explore the impact of dapagliflozin on cardiac function and serum NT-proBNP and cTnⅠ levels of patients with heart failure with reduced ejection fraction(HFrEF).Methods A total of 120 patients with HFrEF were randomly divided into two groups.The control group was treated with standard heart failure drug treatment regimen,and the observation group was treated with dapagliflozin on the basis of the control group.The cardiac function,adverse events and levels of serum NT-proBNP and cTnⅠ were compared between the two groups.Results After treatment,LVEF of the observation group was higher than that of the control group,and LVESD,LVEDD,and levels of serum NT-proBNP and cTnⅠ were lower than those of the control group(P<0.05).The total incidence of adverse events of the observation group was 11.67％,lower than 30.00％of the control group(P<0.05).Conclusions Dapagliflozin can obviously improve the cardiac function of patients with HFrEF,reduce the levels of NT-proBNP and cTnⅠ,and reduce the occurrence of adverse events.
国家科技期刊平台
NSTL
万方数据
维普
